Skip to content

Sutro Biopharma STRO Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$153.6M+19.6%-$191.09M+11.8%-$216.77M-3.9%-$208.7M+14.9%-$245.22M-7.8%
$6.7M-8.5%$7.32M-3.2%$7.57M+1.4%$7.47M+1.5%$7.36M+1.9%
$10.03M-28.4%$14.01M-23.3%$18.27M-21.5%$23.26M-3.7%$24.16M-2.1%
-$151.61M+14.5%-$177.23M+20.4%-$222.53M+10.6%-$248.86M-21.9%-$204.14M-1.6%
$16.01M-64.4%$45.01M-60.4%$113.8M-48.5%$221.1M+60.0%$138.15M-36.8%
$0
$97.57M+3.7%
-$34.45M+74.3%-$134.08M-21.3%-$110.55M-313%-$26.76M-165%$41.01M-66.1%
-$151.59M+14.5%-$177.24M+20.4%-$222.6M+10.8%-$249.43M-21.8%-$204.71M-1.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Sutro Biopharma generate?
Sutro Biopharma (STRO) generated -$151.6M in operating cash flow over the trailing twelve months.
What is Sutro Biopharma's free cash flow?
After $627.0K of capital expenditures, Sutro Biopharma's free cash flow was -$151.6M over the trailing twelve months, up 25.9% year over year.
Where does Sutro Biopharma's cash flow data come from?
Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.